Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC)

Clinical trial NCT03769467 · TERMINATED

Trial details

NCT number: NCT03769467
Sponsor: Atara Biotherapeutics
Status: TERMINATED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Nasopharyngeal Carcinoma Nasopharyngeal Neoplasms Epstein-Barr Virus Infections Epstein-Barr Viraemia Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC)

Start date: 2019-02-19
Primary completion: 2021-08-19
Enrollment: 12

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.